Display Settings:

Format
Items per page

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 58

1.

Heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Multiple subtypes or forms are recognized based on presence or absence of TAU PROTEIN inclusions. FTLD includes three clinical syndromes: FRONTOTEMPORAL DEMENTIA, semantic dementia, and PRIMARY PROGRESSIVE NONFLUENT APHASIA. [from MeSH]

MedGen UID:
148228
Concept ID:
C0751072
2.

Frontotemporal dementia, ubiquitin-positive

The spectrum of frontotemporal dementia associated with GRN (also known as PGRN) mutations (FTD-GRN or FTD-PGRN) includes the behavioral variant (FTD-bv), primary progressive aphasia (PPA; further sub-categorized as progressive non-fluent aphasia [PNFA] and semantic dementia [SD]), and movement disorders with extrapyramidal features such as parkinsonism and corticobasal syndrome. A broad range of clinical features both within and across families is observed. The age of onset ranges from 35 to 87 years. Behavioral disturbances are the most common early feature, followed by progressive aphasia. Impairment in executive function manifests as loss of judgment and insight. In early stages, PPA often manifests as deficits in naming, word finding, or word comprehension. In late stages, affected individuals often become mute and lose their ability to communicate. Early findings of parkinsonism include rigidity, bradykinesia or akinesia (slowing or absence of movements), limb dystonia, apraxia (loss of ability to carry out learned purposeful movements), and disequilibrium. Late motor findings may include myoclonus, dysarthria, and dysphagia. Most affected individuals eventually lose the ability to walk. Disease duration is three to 12 years. [from GeneReviews]

MedGen UID:
375285
Concept ID:
C1843792
Disease or Syndrome
3.

Tissue Degeneration

MedGen UID:
3705
Concept ID:
C0011164
Pathologic Function
4.

Serotonin Reuptake Inhibitor [EPC]

MedGen UID:
453323
Concept ID:
C2911696
Pharmacologic Substance
5.

Selective serotonin re-uptake inhibitor

A type of drug that is used to treat depression. Selective serotonin reuptake inhibitors slow the process by which serotonin (a substance that nerves use to send messages to one another) is reused by nerve cells that make it. This increases the amount of serotonin available for stimulating other nerves. [from NCI]

MedGen UID:
452467
Concept ID:
C0360105
Pharmacologic Substance
6.

Dementia

Loss of intellectual abilities interfering with an individual's social and occupational functions. Causes include Alzheimer's disease, brain injuries, brain tumors, and vascular disorders. [from NCI]

MedGen UID:
99229
Concept ID:
C0497327
Disease or Syndrome
7.

Semantic dementia

MedGen UID:
83268
Concept ID:
C0338462
Mental or Behavioral Dysfunction
8.

Frontotemporal dementia

The clinical manifestations of MAPT-related disorders (MAPT-related tauopathies) are most typically those of frontotemporal dementia (FTDP-17), but also include progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), mild late-onset parkinsonism, and dementia with epilepsy. Clinical presentation of frontotemporal dementia (FTD) is variable: some present with slowly progressive behavioral changes, language disturbances, and/or extrapyramidal signs, whereas others present with rigidity, bradykinesia, supranuclear palsy, and saccadic eye movement disorders. Onset is usually between ages 40 and 60 years, but may be earlier or later. The disease progresses over a few years into profound dementia with mutism. PSP is characterized by progressive vertical gaze palsy in combination with a prominent loss of balance at early stages of the disease. With progression, axial rigidity, dysarthria, and dysphagia become prominent, often in combination with a frontal dysexecutive syndrome. CBD is a progressive neurodegenerative disorder which affects both the frontoparietal cortex and the basal ganglia, resulting in a mild to moderate dementia in combination with asymmetric parkinsonism, ideomotor apraxia, aphasia, and an alien-hand syndrome. [from GeneReviews]

MedGen UID:
83266
Concept ID:
C0338451
Disease or Syndrome
9.

Memantine

AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. [from MeSH]

MedGen UID:
7526
Concept ID:
C0025242
Pharmacologic Substance
10.

Frontotemporal dementia

A dementia associated with degeneration of the frontotemporal lobe and clinically associated with personality and behavioral changes such as disinhibition, apathy, and lack of insight. [from HPO]

MedGen UID:
505124
Concept ID:
CN001944
Finding
11.

Dementia

A loss of global cognitive ability of sufficient amount to interfere with normal social or occupational function. Dementia represents a loss of previously present cognitive abilities, generally in adults, and can affect memory, thinking, language, judgment, and behavior. [from HPO]

MedGen UID:
504574
Concept ID:
CN000683
Finding
12.

Behavioral abnormality

An abnormality of mental functioning including various affective, behavioural, cognitive and perceptual abnormalities. [from HPO]

MedGen UID:
425007
Concept ID:
CN000665
Finding
13.

Onset

The start, beginning, or early stages. [from NCI]

MedGen UID:
87142
Concept ID:
C0332162
14.

Presenile dementia

loss of intellectual functions such as memory, learning, reasoning, problem solving, and abstract thinking while vegetative functions remain intact. [from CRISP]

MedGen UID:
8278
Concept ID:
C0011265
Mental or Behavioral Dysfunction
15.

Alzheimer's disease

Alzheimer disease (AD) is characterized by dementia that typically begins with subtle and poorly recognized failure of memory and slowly becomes more severe and, eventually, incapacitating. Other common findings include confusion, poor judgment, language disturbance, agitation, withdrawal, and hallucinations. Occasionally, seizures, Parkinsonian features, increased muscle tone, myoclonus, incontinence, and mutism occur. Death usually results from general inanition, malnutrition, and pneumonia. The typical clinical duration of the disease is eight to ten years, with a range from one to 25 years. Approximately 25% of all AD is familial (i.e., =2 persons in a family have AD) of which approximately 95% is late onset (age >60-65 years) and 5% is early onset (age <65 years). [from GeneReviews]

MedGen UID:
1853
Concept ID:
C0002395
Disease or Syndrome
16.

Ebixa

MedGen UID:
327650
Concept ID:
C1563959
Pharmacologic Substance
17.

Axura

MedGen UID:
306107
Concept ID:
C1456438
Pharmacologic Substance
18.

tregor

MedGen UID:
303919
Concept ID:
C1448377
Pharmacologic Substance
19.

Gen-Amantadine

MedGen UID:
303918
Concept ID:
C1448370
Pharmacologic Substance
20.

Amixx

MedGen UID:
303917
Concept ID:
C1448368
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...